MX2022012818A - Compuestos triciclicos como inhibidores de egfr. - Google Patents

Compuestos triciclicos como inhibidores de egfr.

Info

Publication number
MX2022012818A
MX2022012818A MX2022012818A MX2022012818A MX2022012818A MX 2022012818 A MX2022012818 A MX 2022012818A MX 2022012818 A MX2022012818 A MX 2022012818A MX 2022012818 A MX2022012818 A MX 2022012818A MX 2022012818 A MX2022012818 A MX 2022012818A
Authority
MX
Mexico
Prior art keywords
compounds
egfr inhibitors
tricyclic compounds
cancers
class
Prior art date
Application number
MX2022012818A
Other languages
English (en)
Inventor
Jianmin Fu
Guosheng Wu
Wei Deng
Zhenhua Tian
Shansong Zheng
Sebastien Andre Campos
Yingying Yang
Qingmei Zheng
Zhiwei Zhao
Leilei Li
Shuyong Zhao
Original Assignee
Qilu Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Qilu Pharmaceutical Co Ltd filed Critical Qilu Pharmaceutical Co Ltd
Publication of MX2022012818A publication Critical patent/MX2022012818A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
    • C07F9/02—Phosphorus compounds
    • C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Se proporcionan una clase de compuestos, representados por la fórmula (I'''), como inhibidores selectivos del EGFR, una composición farmacéutica que contiene los compuestos, intermediarios útiles para preparar los compuestos y un método para usar los compuestos de la presente invención para tratar enfermedades proliferativas de las células, como los cánceres. (ver Fórmula).
MX2022012818A 2020-04-14 2021-04-13 Compuestos triciclicos como inhibidores de egfr. MX2022012818A (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CN202010292186 2020-04-14
CN202010852717 2020-08-22
CN202110175424 2021-02-09
CN202110312259 2021-03-24
PCT/CN2021/086941 WO2021208918A1 (zh) 2020-04-14 2021-04-13 作为egfr抑制剂的三环化合物

Publications (1)

Publication Number Publication Date
MX2022012818A true MX2022012818A (es) 2022-11-14

Family

ID=78083953

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012818A MX2022012818A (es) 2020-04-14 2021-04-13 Compuestos triciclicos como inhibidores de egfr.

Country Status (11)

Country Link
US (1) US20240034743A9 (es)
EP (1) EP4137484A4 (es)
JP (1) JP2023522863A (es)
KR (1) KR20230002721A (es)
CN (1) CN115667226A (es)
AU (1) AU2021256157B2 (es)
BR (1) BR112022019888A2 (es)
CA (1) CA3171776A1 (es)
MX (1) MX2022012818A (es)
WO (1) WO2021208918A1 (es)
ZA (1) ZA202212150B (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN118043329A (zh) * 2021-10-14 2024-05-14 齐鲁制药有限公司 一种三环化合物的用途
CN118076614A (zh) * 2021-10-14 2024-05-24 齐鲁制药有限公司 一种egfr抑制剂的多晶型
WO2024046405A1 (zh) * 2022-09-01 2024-03-07 齐鲁制药有限公司 一种egfr激酶抑制剂的用途

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0421525D0 (en) * 2004-09-28 2004-10-27 Novartis Ag Inhibitors of protein kineses
WO2008051547A1 (en) * 2006-10-23 2008-05-02 Cephalon, Inc. Fused bicyclic derivatives of 2,4-diaminopyrimidine as alk and c-met inhibitors
NZ577197A (en) * 2006-12-08 2011-02-25 Irm Llc Pyrimidine compounds especially 4-phenylamino-2-arylamino-pyrimidine derivatives and compositions as protein kinase inhibitors
US9834518B2 (en) * 2011-05-04 2017-12-05 Ariad Pharmaceuticals, Inc. Compounds for inhibiting cell proliferation in EGFR-driven cancers
CN107540661A (zh) * 2016-06-24 2018-01-05 正大天晴药业集团股份有限公司 作为egfr抑制剂的苯胺嘧啶化合物的结晶
CN110734454B (zh) * 2016-12-12 2021-08-17 石药集团中奇制药技术（石家庄）有限公司 一类含有三环杂芳基的化合物
WO2018108064A1 (zh) * 2016-12-13 2018-06-21 南京明德新药研发股份有限公司 作为第四代egfr激酶抑制剂的螺环芳基磷氧化合物
KR20190114910A (ko) * 2018-03-30 2019-10-10 한미약품 주식회사 상피세포 성장인자 수용체 돌연변이 저해 효과를 갖는 신규 설폰아마이드 유도체

Also Published As

Publication number Publication date
US20230192734A1 (en) 2023-06-22
EP4137484A4 (en) 2023-12-20
ZA202212150B (en) 2023-11-29
WO2021208918A1 (zh) 2021-10-21
CA3171776A1 (en) 2021-10-21
AU2021256157A1 (en) 2022-12-15
CN115667226A (zh) 2023-01-31
AU2021256157B2 (en) 2024-05-02
BR112022019888A2 (pt) 2022-11-22
EP4137484A1 (en) 2023-02-22
KR20230002721A (ko) 2023-01-05
JP2023522863A (ja) 2023-06-01
US20240034743A9 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
ZA202212150B (en) Tricyclic compounds as egfr inhibitors
MX2022008066A (es) Compuestos triciclicos sustituidos.
MX2022006475A (es) Compuestos triciclicos sustituidos.
MX2023010806A (es) 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-onas sustituidas.
JOP20210241A1 (ar) مركبات مدمجة ثلاثية الحلقة مفيدة كعوامل مضادة للسرطان
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
MX2022011601A (es) Compuestos de oxoisoindolina sustituidos para el tratamiento del cancer.
MX2022001784A (es) Piperidinil-metil-purinaminas como inhibidores de nsd2 y antineoplásicos.
CR20220207A (es) Compuestos terapéuticos y métodos de uso
MX2023007554A (es) Compuesto espirocíclico como inhibidor del homólogo del oncogén viral del sarcoma 2 de rata de kirsten con mutación g12c (kras-g12c).
MX2011006821A (es) Derivados de imidazol fusionados como antagonistas de trpv3.
WO2023158679A3 (en) Thiostrepton-inspired compounds for treatment of cancer and preparation thereof
MX2023011829A (es) Derivados de uracilo como inhibidores de trpa1.
ZA202206266B (en) Pd-l1 antagonist compound
MX2023009379A (es) Derivados de tetrahidroazepina biciclicos para el tratamiento del cancer.
MX2022016357A (es) Derivados de tetrazol como inhibidores de trpa1.
MX2023010942A (es) Moduladores de sting (estimulador de genes de interferon).
CR20220668A (es) Derivados de tetrazol como inhibidores de trpa1
MX2023007550A (es) Compuestos de aminobencil heteroarilo sustituidos como inhibidores de receptor de factor de crecimiento epidermico (egfr) y/o fosfoinositol 3-cinasa (pi3k).
MX2022013890A (es) Sintesis y derivados de acido boronico, formas polimorficas y usos terapeuticos de los mismos.
MX2022002941A (es) Cristal de derivado de 1,3,5-triazina o solvato del mismo y metodo para producir el mismo.
MX2021012417A (es) Anillos de piridina que contienen derivados como inhibidores de malt1.
EA201190003A1 (ru) Производные хроменона в качестве trpv3 антагонистов
MX2023004009A (es) Derivados de tetrazol como inhibidores de trpa1.
MX2023004008A (es) Derivados de tetrazol como inhibidores de trpa1.